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Abstract 
The phenomenon of the endoplasmic reticulum (ER) stress as a molecular pathophysiological process 
underlies diseases as cancer, diabetes mellitus, myocardial infarction, neurodegenerative disorders, 
diseases of the urinary system, disorders associated with bone integrity, etc. To prevent ER stress, 
salubrinal, which is a phosphatase inhibitor of the eukaryotic translation initiation factor - 
GADD34:PP1, is currently being intensively studied. The aim of this work is to search for new 
analogues of this drug using molecular docking methods. Optimization of the geometry of the studied 
structures and molecular docking was carried out using the ArgusLab 4.0.1 software package. The 
three-dimensional crystal structure of the GADD34: PP1 enzyme (PDB ID: 4XPN) was loaded in the PDB 
format from the protein molecule data bank. The model of the binding site was created on the basis 
of the phosphoric acid residue (403 PO4). The dimensions of the binding site were set manually and 
were 40.000 Å along the X-axis, 40.000 Å - the Y-axis and 40.000 Å - the Z-axis. The docking was done 
with a flexible ligand, and the semi-empirical AScore function was used for the scoring procedure. It 
was shown that for the salubrinal molecule the most favorable was the conformation stabilized by the 
intramolecular hydrogen bond formed between the hydrogen atom of the thiourea fragment and the 
oxygen atom of the amide fragment. According to molecular docking data, six compounds from the 
fifty-four analyzed analogues of salubrinal exceed it in the stability of the complex formed with 
GADD34:PP1. The results of this work can be used to create new phosphatase inhibitors of the 
eukaryotic translation initiation factor GADD34:PP1. 
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Introduction 
Endoplasmic reticulum (ER) is an intracellular membrane organelle that is extremely sensitive to 
changes in homeostasis. The membrane ER is integrated with the cell nucleus membrane. The internal 
ER space opens directly into the perinuclear space, which accompanies the contact of the ER signalling 
device with the genetic material. There are granular (rough) ER and agranular (smooth) ER. Smooth ER 
is located on the periphery of the organelle and is responsible for the synthesis of lipids, steroids, the 
metabolism of carbohydrates, medicines and other exogenous products [1,2]. 
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Rough ER is an extension of the cell nucleus membrane. On its cytosolic surface, ribosomes are 
deposited, which provide for the translation of the protein directly into the ER cavity through the 
system of transmembrane channels. Inside the granular ER, "immature" protein molecules are 
foldable, i.e. take a correct spatial conformation. All unfolded or incorrectly folded proteins are caught 
and necessarily destroyed. Accumulation of misfolded protein molecules results in a functional 
overload of ER. This phenomenon is called ER stress and it leads to disorders in the normal functioning 
of the cell and threatens it with death [1,2]. 
 
Figure 1. Schematic simplified image of the main signal-sensory systems of ER stress 
Over the past 15 years [3], molecular mechanisms of ER stress have been intensively studied as a 
fundamental phenomenon of cell protection from the action of various factors and as a molecular 
pathophysiological process leading to many severe diseases [3-21]. 
Figure 1 schematically depicts the response of the cell to ER stress, which is necessary for the cell 
to find ways to escape from the state of stress caused by the accumulation of unfolded or misfolded 
proteins, and which is mediated by three signal-sensory systems that begin in the ER lumen and 
terminate in the cytoplasm and nucleus [22-26]. Induction of ER stress stops the penetration of 
synthesized proteins into it and accompanies both the proper folding of proteins, which are already in 
it and the degradation of misfolded ones. This is necessary for the survival of the cell under the 
conditions of the factors that induce this stress, or death of the cell through the apoptosis system 
associated with ER [27,28]. 
The main signal-sensory ER stress systems (PERK, ATF6 and IRE1), which originate in its lumen 
under the conditions of accumulation of unfolded or incorrectly folded proteins in it, initiate total 
repression of translation initiation by phosphorylation of eukaryotic translation initiation factor 2α 
(eIF2α), and activation of the transcription of stress dependent genes by the formation of an active 
form of transcription factors ATF4 and ATF6, as well as an alternative splice variant of the transcription 
factor XBP1 (X-Box Protein-1), which controls the expression of the cell genes [19,26]. 
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In this way, the response of cells to ER stress, which is mediated by the three signal-sensory 
systems, is necessary for the cell to find possible ways out of the state of stress caused by the 
accumulation of unfolded or incorrectly folded proteins in the ER lumen. 
EIF2α is a key participant in protein translation because it is responsible for binding the 40S 
ribosomal subunit to tRNAimet (initiation of methionine tRNA), which recognizes the mRNA start codon 
and starts the synthesis of the peptide chain [19]. PERK phosphorylates eIF2α translating it into an 
inactive eIF2αP form. However, the holoenzyme complex GADD34: PP1 dephosphorylates eIF2αP, 
again translating it into an active eIF2α form. 
In 2005, M. Boyce and colleagues reported that salubrinal (Fig. 2) acted as a phosphatase inhibitor 
GADD34:PP1, selective for eukaryotic translation initiation factor 2α (eIF2α) [29]. Thus, salubrinal 
weakens the synthesis of unfolded or misfolded proteins contributing to the preservation of 
homeostasis in ER and saving cells from apoptosis. 
 
Figure 2. Structure of the salubrinal molecule 
Since the beginning of intensive studies of salubrinal, its protective effect has been confirmed in a 
number of studies [30]. Although salubrinal is currently under development, we can already say with 
certainty about its prospects in the treatment of diabetes [31], myocardial infarction [32], 
neurodegenerative disorders [33,34], oncological diseases [35], diseases of the genitourinary system 
[36] and disorders related to the integrity of bone tissue [37,38]. Work is underway to study its 
toxicity and the development of analogues [39]. 
In this paper, using the methods of molecular docking [40,41], we have established the binding site 
of the salubrinal preparation with holoenzyme GADD34:PP1 and searched for analogues of this drug. 
Materials and methods  
Computer specification 
All calculations were carried out on a Toshiba personal computer, the Satellite L650D model, AMD 
Phenom(tm) II P820 Triple-Core Processor. A 64-bit operating system was used. 
Ligand preparation 
The search for structures for research was conducted in the SciFinder database 
(https://scifinder.cas.org) (see supporting information). Prior to molecular docking, the structures of 
all the compounds studied were optimized within the semiempirical PM3 method [42] using the 
ArgusLab 4.0.1 software package [43-47]. The calculation of the electron density distribution in the 
static salubrinal molecule was carried out with the ZINDO approximation method [48] in the same 
software package. 
Protein preparation  
The three-dimensional crystal structure of the GADD34:PP1 enzyme (4XPN) was loaded in the PDB 
format from the protein molecules data bank (http://www.rcsb.org). Prior to docking, the molecules 
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of all the non-proteinaceous components, except for one phosphoric acid residue, having the code in 
co-crystallisate 403 PO4, were removed. Hydrogen atoms were added throughout the protein 
structure before molecular docking. 
Molecular docking procedure 
Based on the phosphoric acid residue (403 PO4), a ligand group was created with the given name 
Ligand_X-ray. Based on this group, a three-dimensional model of a binding site was created, the 
dimensions of which were set manually and amounted along the X-axis – 40.000 Å, the Y-axis – 
40.000 Å and the Z-axis – 40.000 Å. Docking was performed with a flexible ligand. For the scoring 
procedure, the semi-empirical function AScore was used created on the basis of the XScore function 
[49]. The resolution of the cell was set at 0.250 Å. The calculation type was Dock; Docking Engine - 
ArgusLab. Visualization of the results was carried out using the program PyMOL [50]. 
Results and discussion 
The results of ligand geometry optimization  
According to the results of optimization of the geometry of the salubrinal molecule, the most 
stable is the conformation stabilized by the intramolecular hydrogen bond formed between the 
hydrogen atom of the thiourea fragment and the oxygen atom of the amide fragment (Fig. 3a). The 
length of the NH...O=C bond is 1.891 Å. That is, the salubrinal molecule exists as a pseudo 1,3,5-
oxadiazine ring with an angle H...O=C 108.33 °. According to X-ray diffraction data for 1,3,5-oxadiazine 
cycles, this angle is somewhat larger and lies within the range of 114.76-120.00° [51-53]. The 
appearance of an intramolecular hydrogen bond is obviously associated with a large difference in the 
static charges on the oxygen atom of the amide fragment and the hydrogen atom of the thiourea 
fragment. According to calculations of the electron density distribution in the static salubrinal 
molecule (the ZINDO approximation method), on the oxygen atom δ- lies within -0.0409→-0.0500, in 
turn, on the hydrogen atom δ
+
 is 0.0500→0.0409 (Fig. 3b). The presence of an intramolecular 
hydrogen bond is characteristic of all the salubrinal analogues studied (see Supporting information, 
Tables S1 and S2). 
 
Figure 3. a) The calculated structure of the salubrinal molecule (PM3 method), visualization in PyMol; b) 
Distribution of electron density in the static salubrinal molecule. Colors:  a) □ 0.0500 → 0.0409; b) ■ 
0.0409 → 0.0318; c) ■ 0.0318 → 0.0227; d) ■ 0.0227 → 0.0136; e) ■ 0.0136 → 0.0045; f) ■ 0.0045 → -
0.0045; g) ■ -0.0045 → -0.0136; h) ■ -0.0136 → -0.0227; i) ■ -0.0227 → -0.0318; j) ■ -0.0318 → -0.0409; 
k) ■ -0.0409 → -0.0500 
The results of molecular docking 
The active center of selective dephosphatase of the eukaryotic translation initiation factor (Fig. 4a) 
contains the phosphoric acid residue, and two Mg2+ ions (not shown in the figure). In the active site of 
the GADD34:PP1, it is possible to distinguish three sites, one hydrophilic - located approximately in its 
center, and two lipophilic ones located on the periphery. Therefore, the interactions of the salubrinal 
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molecule with the active site of the GADD34:PP1 enzyme are represented by both polar contacts (Fig. 
4b) and lipophilic interactions between the cinnamic acid residue, the quinoline ring and the lipophilic 
regions of the active site. The molecule of salubrinal effectively interacts with the GADD34:PP1 
enzyme closing access to the active site. The energy of the complex GADD34:PP1-salubrinal forms -
12.2489 kcal/mol. The salubrinal molecule is additionally fixed in the active center of the enzyme due 
to the formation of an intermolecular hydrogen bond involving the amino acid Tyr 272 (Fig. 4b). A 
hydrogen bond arises between the nitrogen atom of the pyridine type of the quinoline ring and the 
hydroxyl group of Tyr 272 (the length of the N...HO bond is 3.432 Å). The salubrinal molecule is also 
fixed due to the shortened intermolecular polar contacts: 1) between the oxygen atom of the amide 
fragment and the hydroxyl group Tyr 134; 2) between the sulfur atom of the thiourea fragment and 
the guanidine fragment Arg 221. 
 
Figure 4. a) The structure of the GADD34:PP1 holoenzyme. Protein phosphatase 1 (PP1) is represented 
in white color, and GADD34 - pink light. In the active site of the holoenzyme, there is a phosphoric acid 
residue, depicted in the form of spheres; b) the orientation of the salubrinal molecule in the active site 
of the GADD34:PP1 holoenzyme according to molecular docking data. 
To determine the effect of the residue of cinnamic acid and quinoline cycle in the salubrinal 
preparation on the ability to bind to the active site of the GADD34:PP1 enzyme, we periodically 
replaced one of the fragments with other groups. According to the molecular docking data, six 
compounds out of fifty-four analyzed salubrinal analogues (see supporting information Table S3 and 
S4) exceeded it in the stability of the complex formed with GADD34:PP1 (Fig. 5). 
The most stable complex with GADD34:PP1 is formed by (E)-3-(thiophen-2-yl)-N-(2,2,2-trichloro-1-
(3-(quinolin-8-yl)thioureido)ethyl)acrylamide (S1) (Fig. 6a), the energy of the complex with 
GADD34:PP1 is -12.8833 kcal/mol, RMSD 1.4 Å. The molecule of the compound (S1) is additionally 
fixed in the enzyme active site due to the intermolecular hydrogen bond formed between the 
nitrogen atom of the thiourea fragment and the -OH group of Tyr 272, the length of the HN...HO bond 
is 3.605 Å). It is also fixed due to the formation of shortened intermolecular polar contacts: 1) 
between the oxygen atom of the amide fragment and the hydroxyl group of Tyr 134; 2) between the 
sulfur atom of the thiourea fragment and the guanidine fragment Arg 221. 
The energy of the complex N-(2,2,2-trichloro-1-(3-(2-chlorophenyl)thioureido)ethyl)cinnamamide 
(S2) with GADD34:PP1 forms -12.5738 kcal/mol, RMSD 2.3 Å (Fig. 6b). The molecule of the compound 
(S2) is additionally fixed in the active site of the enzyme due to the formation of two intermolecular 
hydrogen bonds involving amino acids His 125 and Asn 124 (Fig. 6b). Both hydrogen bonds are formed 
by the oxygen atom of the amide fragment. In the first case, the hydrogen bond is with the pyrrole 
atom of nitrogen of the imidazole ring His 125 (the C=O...HN bond length is 2.133 Å), and in the 
second case - with the amide fragment of amino acid Asn 125 (the C=O...H2NC(O) bond length is 2.884 
Å). The molecule of the compound (S2) is also fixed due to the shortened intermolecular polar contact 
between the sulfur atom of the thiourea fragment and the guanidine fragment Arg 221. 
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Figure 5. Structures of salubrinal analogues, surpassing it in the strength of the salubrinal preparation 
superior to the strength of the formed complex with the GADD34:PP1 holoenzyme. 
 
N-(2,2,2-Trichloro-1-(3-(naphthalen-2-yl)thioureido)ethyl)cinnamamide (S3) forms the complex 
with the GADD34:PP1 enzyme having the energy of -12.4218 kcal/mol, RMSD 1.4 Å (Fig. 6c). The 
molecule of the compound (S3) is additionally stabilized in the enzyme active center due to the 
intermolecular hydrogen bond formed by the oxygen atom of the oxygen amide fragment and the HN 
group of Tyr Arg 221, the C=O...HN bond length is 2.481 Å. The molecule of the compound (S3) is also 
stabilized due to the shortened intermolecular polar contact between the sulfur atom of the thiourea 
fragment and the guanidine fragment Arg 221. 
The energy of the complex N-(2,2,2-trichloro-1-(3(naphthalene-1-yl)thioureido)ethyl)cinnamamide 
(S4) with GADD34:PP1 forms -12.4195 kcal/mol, RMSD 4.8 Å (Fig. 6d). The molecule of the compound 
(S4) is additionally stabilized in the enzyme active center due to the formation of intermolecular 
hydrogen bonds: 1) between the oxygen atom of the amide fragment and the -OH group of Tyr 134, 
the C=O...HO bond length is 2.758 Å; 2) between the nitrogen atom of the thiourea fragment and the -
OH group of Tyr 272, the HN...HO bond length is 2.999 Å. Moreover, stabilization occurs due to the 
shortened intermolecular polar contact between the sulfur atom of the thiourea fragment and the 
guanidine fragment Arg 221. 
(E)-3-(Thiophen-3-yl)-N-(2,2,2-trichloro-1-(3-(quinolin-8-yl)thioureido)ethyl)acrylamide (S5) and N-
(2,2,2-trichloro-1-(3-(4-chlorophenyl)thioureido)ethyl)cinnamamide (S6) form complexes with the 
GADD34:PP1 enzyme having the energy of -12.3286 kcal/mol (RMSD - 1.3 Å) and -12.3140 kcal/mol 
(RMSD - 5.4 Å), respectively (Fig. 6e, 6f). The compounds (S5) and (S6) do not form intermolecular 
hydrogen bonds in the active center of GADD34:PP1, their interaction with amino acids forming the 
active site is obviously hydrophobic in nature. In this case, the formation of weak shortened 
intermolecular polar contacts is possible, for example, between the sulfur of the thiourea fragment 
and the guanidine fragment Arg 221. It should be noted, that the molecule of the compound (S6) in 
the active center of GADD34:PP1 is rotated 180° as compared to the salubrinal molecule and the 
remaining compounds hits. 
Figure 7 shows that for both quinoline derivatives and cinnamic acid derivatives, the energy of the 
complex formed is clearly related to GADD34:PP1 from the RMSD value. The quinoline derivatives 
interact closely with the active site of the enzyme, the RMSD value does not exceed 3.5 Å. While for 
the cinnamic acid derivatives, RMSD can vary from 1.5 to 12.0 Å. This is due to the fact that there are 
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two lipophilic sites in the active center of the enzyme. The quinoline cycle, due to spatial difficulties, is 
clearly fixed only in one of them, and the cinnamic acid residue can interact with both. This can lead to 
a reversal of the inhibitor molecule located in the active center by 180° relative to the salubrinal 




Figure 6. Position of the molecules of the compounds (S1)-(S6) in the active center of the GADD34:PP1 
holoenzyme. 
 
Figure 7. Energy dependence of the complex GADD34:PP1-Inhibitor on the RMSD value. Color: a) ■ 
quinoline derivatives; ■ cinnamic acid derivatives; ■ salubrinal, taken into account when constructing a 
linear regression line in both cases. 
Based on our findings, when searching for the GADD34:PP1 inhibitors, other than cinnamic acid 
and quinoline derivatives, special attention should be paid to the compounds containing a 
naphthalene and isoquinoline ring, heterocyclic analogs of cinnamic acid, and compounds containing 
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chlorine atoms in the aromatic ring. The results of our work are in good agreement with the already 
published experimental data on establishing the dependence of the structure-activity of salubrinal 
analogues [39,54]. For example, the low activity of 2-amino-pyridine derivatives, for which the EC50 
lies in the range of 28-72 μM [39], as compared to the derivatives of 8-aminoquinoline  
(EC50 = 15-16 μM) [39,54], can be explained by the high energy of the complex that they form with 
GADD34:PP1. The lower energy of the GADD34:PP1-Inhibitor complex can also explain the high 
efficiency of (E)-3-(thiophen-2-yl)acrylamide derivatives (EC50 = 4-43 μM) compared with cinnamamide 
derivatives (EC50 = 6-57 μM) [54]. 
Conclusions 
In this paper, the search for new analogues of salubrinal has been carried out by molecular 
modeling. We have shown that the most stable conformation of the salubrinal molecule and its 
analogues contains the intramolecular hydrogen bond between the hydrogen atom of the thiourea 
fragment and the oxygen atom of the amide fragment. The binding site of salubrinal to the active site 
of the enzyme has been established. We have found the compounds, which form stronger complexes 
with the enzyme than salubrinal itself. The results of this work can be used to create new phosphatase 
inhibitors of the eukaryotic translation initiation factor GADD34:PP1. 
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Table S1. The results of geometry optimization of salubrinal analogues containing cinnamic acid residue 
 
Entry R CAS No E, kcal/mol 
The length of the NH...O=C 
bond, Å 





405060-59-9 -111285.9025 1.891 108.33 347 
2 
 
863036-22-0 -111285.2829 1.880 108.88 348 
3 
 
294654-78-7 -110631.9704 2.273 105.11 344 
4 
 
324769-18-8 -110634.7191 1.863 108.63 365 
5 
 
405060-99-3 -98255.3837 1.919 109.47 192 
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6 
 
405060-96-0 -104370.9745 1.883 108.96 207 
7 
 
863036-35-5 -129157.9187 1.943 108.52 736 
8 
 
301359-85-3 -99001.5764 1.891 108.31 232 
9 
 
301359-95-5 -102453.0936 1.863 108.48 272 
10 
 
301359-86-4 -102454.5158 1.864 108.24 240 
11 
 
301359-87-5 -102454.6059 1.868 108.08 249 
12 
 
1429483-71-5 -105904.3082 1.863 108.55 315 
13 
 
301359-93-3 -105905.3171 1.865 108.40 288 
14 
 
301359-94-4 -105905.2465 1.861 108.55 287 
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15 
 
294657-79-7 -105777.6924 1.858 107.98 247 
16 
 
3037775-31-7 -105778.1081 1.890 108.48 271 
17 
 
405060-94-8 -103291.5220 1.863 108.80 246 
18 
 
301359-88-6 -109214.6095 1.874 108.24 288 
19 
 
1346508-38-0 -109215.6380 1.886 108.42 298 
20 
 
303775-35-5 -115287.0750 1.858 108.47 295 
21 
 
294655-14-4 -115289.4152 1.870 108.75 318 
22 
 
294655-12-2 -118722.8463 1.858 108.12 359 
23 
 
294654-81-2 -115870.4210 1.871 108.65 291 
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294654-82-3 -115870.3348 1.868 108.55 301 
25 
 
301359-89-7 -105946.6228 1.864 108.36 241 
26 
 
301359-90-0 -105947.3592 1.860 108.50 224 
27 
 
301359-91-1 -105947.5373 1.859 108.49 234 
28 
 
301359-92-2 -106797.8334 1.860 108.54 237 
29 
 
301359-97-7 -112891.5613 1.862 108.63 254 
30 
 
301359-98-8 -112891.2835 1.863 108.60 277 
31 
 
301359-96-6 -138810.5173 1.859 108.45 355 
32 
 
301815-13-4 -116057.8543 1.863 108.53 375 
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294653-17-1 -124258.2307 1.896 108.75 723 
34 
 
294654-77-6 -120926.7177 1.862 108.67 409 
35 
 
863036-23-1 -99655.3253 1.857 108.48 215 
36 
 
1349267-41-9 -110899.9614 1.873 108.85 294 
37 
 
1349267-41-9 -112093.4153 2.339 104.89 272 
38 
 
1346508-37-9 -97718.9301 2.507 105.22 233 
39 
 
1346508-36-8 -101035.0119 2.521 105.03 225 
40 
 
1429483-72-6 -101809.4188 2.493 105.51 275 
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Table S2. The results of geometry optimization of salubrinal analogues containing quinoline ring 
 
Entry R CAS No E, kcal/mol 
The length of the  
NH...O=C bond, Å 




1 CH3- 294658-37-0 -90772.1333 1.835 109.78 141 
2 
 
324769-75-5 -97666.2121 1.849 109.08 207 
3 
 
294658-28-9 -101115.4287 1.832 109.23 261 
4 (CH3)3C- 412962-51-7 -101113.4907 1.843 109.50 247 
5 
 
305856-11-5 -108568.4619 2.370 101.87 319 
6 
 
294646-80-3 -105112.9884 2.387 101.67 291 
7 
 
324017-95-0 -108568.5668 2.460 101.65 323 
8 
 
330684-99-6 -108574.0942 2.261 105.45 330 
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294658-30-3 -108574.2167 2.418 105.03 313 
10 
 
330567-60-7 -112916.8710 2.288 104.53 308 
11 
 
294658-45-0 -115333.8079 2.382 102.98 363 
12 
 
405060-98-2 -116754.1849 2.262 104.94 437 
13 
 
324017-57-4 -105701.1794 2.347 102.79 246 
14 
 
1346508-21-1 -109395.6421 1.901 108.14 336 
15 
 
1346508-22-2 -109398.3840 1.913 107.96 313 
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Table S3. The results of molecular docking of salubrinal analogues containing cinnamic acid residue 
 





405060-59-9 -12.2489 - 68 
2 
 
863036-22-0 -11.4506 9.8 64 
3 
 
294654-78-7 -12.4195 4.8 66 
4 
 
324769-18-8 -12.4218 1.4 68 
5 
 
405060-99-3 -10.4440 8.6 222 
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405060-96-0 -10.9403 8.7 712 
7 
 
863036-35-5 -11.0821 6.3 25055 
8 
 
301359-85-3 -11.0494 2.4 91 
9 
 
301359-95-5 -11.8415 2.5 78 
10 
 
301359-86-4 -11.7071 3.4 81 
11 
 
301359-87-5 -10.9713 9.5 82 
12 
 
1429483-71-5 -11.4002 3.5 70 
13 
 
301359-93-3 -11.0643 2.6 74 
14 
 
301359-94-4 -10.7865 6.86 70 
ADMET & DMPK 7(2) (2019) S1-S15 Molecular docking studies of salubrinal: supplementary information 
doi: 10.5599/admet.632 S11 
15 
 
294657-79-7 -11.9634 2.8 76 
16 
 
3037775-31-7 -10.8881 6.7 80 
17 
 
405060-94-8 -11.2845 2.0 75 
18 
 
301359-88-6 -11.3522 3.6 152 
19 
 
1346508-38-0 -9.8336 5.5 182 
20 
 
303775-35-5 -11.7954 3.4 176 
21 
 
294655-14-4 -10.0874 3.4 202 
22 
 
294655-12-2 -11.1046 3.7 501 
23 
 
294654-81-2 -9.9688 4.2 201 
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294654-82-3 -10.2628 11.0 195 
25 
 
301359-89-7 -12.5738 2.3 86 
26 
 
301359-90-0 -10.2843 3.2 88 
27 
 
301359-91-1 -12.3140 5.4 88 
28 
 
301359-92-2 -10.4781 10.6 87 
29 
 
301359-97-7 -10.5242 9.6 82 
30 
 
301359-98-8 -11.0901 9.8 77 
31 
 
301359-96-6 -10.5026 8.7 140 
32 
 
301815-13-4 -10.9633 6.9 178 
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294653-17-1 -11.6777 6.8 45 
34 
 
294654-77-6 -10.2446 10.0 108 
35 
 
863036-23-1 -9.8478 11.1 87 
36 
 
1349267-41-9 -10.0146 11.9 60 
37 
 
1349267-41-9 -9.5065 6.9 60 
38 
 
1346508-37-9 -10.1080 4.1 35 
39 
 
1346508-36-8 -10.0909 6.1 35 
40 
 
1429483-72-6 -10.3209 5.5 31 
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Table S4. The results of molecular docking of salubrinal analogues containing quinoline ring 
 
Entry R CAS No E, kcal/mol RMSD, Å 
Time, 
seconds 
1 CH3- 294658-37-0 -9.5079 3.4 30 
2 
 
324769-75-5 -9.5363 3.3 37 
3 
 
294658-28-9 -10.1110 3.4 48 
4 (CH3)3C- 412962-51-7 -10.5443 2.4 35 
5 
 
305856-11-5 -11.0971 3.5 55 
6 
 
294646-80-3 -12.0377 1.3 38 
7 
 
324017-95-0 -12.0111 3.3 34 
8 
 
330684-99-6 -10.2993 2.6 37 
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294658-30-3 -10.9900 1.9 36 
10 
 
330567-60-7 -11.9627 3.4 36 
11 
 
294658-45-0 -10.4252 2.4 54 
12 
 
405060-98-2 -11.1993 2.4 35 
13 
 
324017-57-4 -9.8686 1.4 38 
14 
 
1346508-21-1 -12.8833 1.4 74 
15 
 
1346508-22-2 -12.3286 1.3 75 
 
 
 
 
 
 
 
